Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cinitapride→

Cinitapride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
66564-14-5
Molecular formula
C21H30N4O5
Molecular weight
418.5 g/mol
Drug class
Prokinetic substituted-benzamide5-HT receptor agonist and dopamine D2 antagonist
Mechanism of action
Acts as a 5-HT4 agonist and dopamine D2 antagonist; stimulation of enteric 5-HT4 receptors enhances acetylcholine release and gastrointestinal motility. Published pharmacology also describes 5-HT1 agonist and 5-HT2 antagonist activity.
Indications / reported uses
  • Functional dyspepsia, particularly postprandial-distress or dysmotility-predominant symptoms, in jurisdictions where cinitapride is authorised

Sources: PubMed phase III trial · PubMed clinical study · PubChem / ChEBI summary

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cinitapride Environmental Risk Assessment (ERA) (the Cinitapride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.